Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Condition(s):NeuroblastomaLast Updated:September 28, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):NeuroblastomaLast Updated:September 28, 2023Recruiting
Condition(s):Pseudofolliculitis BarbaeLast Updated:January 31, 2024Terminated
Condition(s):MedulloblastomaLast Updated:September 28, 2023Recruiting
Condition(s):NeuroblastomaLast Updated:September 28, 2023Recruiting
Condition(s):Familial Adenomatous PolyposisLast Updated:June 8, 2021Completed
Condition(s):Other Benign Neoplasm of Skin, UnspecifiedLast Updated:March 23, 2017Completed
Condition(s):Anaplastic Astrocytoma; Recurrent Anaplastic AstrocytomaLast Updated:January 21, 2022Unknown status
Condition(s):Prostate CancerLast Updated:May 14, 2018Completed
Condition(s):Familial Adenomatous PolyposisLast Updated:April 24, 2015Withdrawn
Condition(s):HirsutismLast Updated:December 2, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.